ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

REPL Replimune Group Inc

6.83
-5.49 (-44.56%)
After Hours
Last Updated: 16:08:48
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Replimune Group Inc REPL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-5.49 -44.56% 6.83 16:08:48
Open Price Low Price High Price Close Price Prev Close
6.10 5.89 7.23 6.7458 12.32
more quote information »

Recent News

Date Time Source Heading
12/05/20239:35IHNWFeaturedInternational Lithium: PEA for the Raleigh Lake Lithium Project Outlines Highly Favourable After-Tax NPV (Discounted at 8%) of CAD$342.9 million and After-Tax IRR of 44.3% P.A.
12/05/20237:30IHNWFeaturedProspera Energy Inc. Secures $3.5 Million in Development Financing and Announces Strategic Appointments to Strengthen Leadership Team
12/05/202307:19EDGAR2Form 8-K - Current report
12/05/202307:00GLOBEReplimune Shares Initial Primary Analysis Results from..
11/17/202320:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/17/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/08/202309:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
11/07/202317:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202308:15EDGAR2Form 8-K - Current report
11/07/202308:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
11/03/202319:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
9/20/202320:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/20/202320:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
9/19/202316:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
9/19/202308:15EDGAR2Form 8-K - Current report
9/19/202308:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
9/13/202321:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/07/202309:17EDGAR2Form 8-K - Current report
8/24/202320:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/15/202320:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/03/202309:04EDGAR2Form 8-K - Current report
8/03/202308:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
8/03/202308:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/202308:09EDGAR2Form 8-K - Current report
8/03/202308:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
8/01/202308:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
7/31/202316:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
7/26/202320:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
7/26/202317:08EDGAR2Form ARS - Annual Report to Security Holders
7/26/202317:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
7/26/202317:02EDGAR2Form DEF 14A - Other definitive proxy statements
7/20/202308:56EDGAR2Form 8-K - Current report
7/20/202308:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
7/11/202321:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/10/202316:27EDGAR2Form 144 - Report of proposed sale of securities
6/06/202310:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
6/05/202308:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
6/03/202314:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..
6/01/202316:01GLOBEReplimune to Present at the Jefferies Global Healthcare..
5/25/202317:00GLOBEReplimune to Present at the 2023 American Society of..
5/18/202308:00GLOBEReplimune Reports Fiscal Fourth Quarter and Year Ended 2023..
5/09/202308:00GLOBEReplimune to Participate in the Piper Sandler Spring..
3/08/202308:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
2/09/202308:00GLOBEReplimune Reports Fiscal Third Quarter Financial Results and..
2/07/202308:00GLOBEReplimune to Present at the Virtual SVB Securities Global..
1/04/202308:05GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
1/04/202308:00GLOBEReplimune Appoints Former Sanofi U.S. Commercial Oncology..
1/03/202308:00GLOBEReplimune to Present at the 41st Annual J.P. Morgan..
12/08/202221:04GLOBEReplimune Announces Pricing of Public Offering
12/08/202208:45TRMNReplimune Group (REPL) Gets a Buy from Jefferies
12/07/202216:04GLOBEReplimune Announces Proposed Public Offering
12/07/202215:25TRMNSVB Securities Sticks to Its Buy Rating for Replimune Group..

Your Recent History

Delayed Upgrade Clock